ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
Status:
Terminated
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
This randomized phase IIb trial studies how well ACTOplus met XR works in treating in
patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive
treatment. Chemoprevention is the use of drugs to keep oral cavity or oropharynx cancer from
forming or coming back. The use of ACTOplus met XR may slow disease progression in patients
with oral cavity or oropharynx cancer.